Relation of Blood Arsenic Concentration with Effect and Safety of Arsenic-Containing Qinghuang Powder (青黄散) in Patients with Myelodysplastic Syndrome

Objective: To investigate the relation of blood arsenic concentration(BAC) with clinical effect and safety of arsenic-containing Qinghuang Powder(青黄散, QHP) in patients with myelodysplastic syndrome(MDS). Methods: Totally 163 patients with MDS were orally treated with QHP for 2 courses of treatment, 3 months as 1 course. The BACs of patients were detected by atomic fluorescence spectrophotometry at 1, 3, and 6 months during the treatment, and the effective rate, hematological improvement and safety in patients after treatment with QHP were analyzed. Results: After 2 courses of treatment, the total effective rate was 89.6%(146/163), with 31.3%(51/163) of hematological improvement and 58.3%(95/163) of stable disease. The hemoglobin increased from 73.48±19.30 g/L to 80.39±26.56 g/L(P0.05), the absolute neutrophil count increased from 0.81±0.48×10~9/L to 1.08±0.62×10~9/L(P0.05), and no significant changes were observed in platelet counts(P0.05). Among 46 patients previously depended on blood transfusion, 28.3%(13/46) completely got rid of blood transfusion and 21.7%(10/46) reduced the volume of blood transfusion by more than 50% after treatment. The BACs were significantly increased in patients treated for 1 month with 32.17±18.04 μg/L(P0.05), 3 months with 33.56±15.28 μg/L(P0.05), and 6 months with 36.78±11.92 μg/L(P0.05), respectively, as compared with those before treatment(4.08±2.11 μg/L). There were no significant differences of BACs among the patients treated for 1, 3 and 6 months(P0.05). The adverse reactions of digestive tract during the treatment were mild abdominal pain and diarrhea in 14 cases(8.6%), and no patients discontinued the treatment. The BACs of patients with gastrointestinal adverse reactions were significantly lower than those without gastrointestinal adverse reactions(22.39±10.38 vs. 37.89±11.84, μg/L, P0.05). The BACs of patients with clinical effect were significantly higher than those failed to treatment(40.41±11.69 vs. 23.84±12.03, μg/L, P0.05). Conclusion: QHP was effective and safe in the treatment of patients with MDS and the effect was associated with BACs of patients.     

《内经》所蕴含的中医肾病证治思路探讨

邹氏肾科医术非物质文化遗产团队根据《内经》相关理论结合团队临床实践对常见肾病的中医证治思路进行探讨,认为肾气不足为肾病发病之因,肾元衰竭是发病之本。临床中需注意未病先防、既病防变,强调治病必求于本。根据临床实际情况,分别提出从脾肾、从肝肾、从肺论治肾病,常用治法有健脾温肾、扶正渗利、清肝解毒、养肝滋阴、平肝潜阳、疏肝活络、疏风宣肺、清热宣肺、清热利咽、和法缓治、活血化瘀、疏滞泄浊等法。      

Impact of corneal parameters on intraocular pressure measurements in different tonometry methods

AIM: To evaluate the impact of central corneal thickness (CCT) and corneal curvature on intraocular pressure (IOP) measurements performed by three different tonometers. METHODS: IOP in 132 healthy eyes of 66 participants was measured using three different tonometry techniques: Goldmann applanation tonometer (GAT), Pascal dynamic contour tonometer (DCT), and ICare rebound tonometer (RT). CCT and corneal curvature were assessed. RESULTS: In healthy eyes, DCT presents significantly higher values of IOP than GAT (17.34±3.69 and 15.27±4.06 mm Hg, P<0.0001). RT measurements are significantly lower than GAT (13.56±4.33 mm Hg, P<0.0001). Compared with GAT, DCT presented on average 2.51 mm Hg higher values in eyes with CCT<600 μm and 0.99 mm Hg higher results in eyes with CCT≥600 μm. The RT results were lower on average by 1.61 and 1.95 mm Hg than those obtained by GAT, respectively. Positive correlations between CCT in eyes with CCT<600 μm were detected for all IOP measurement techniques, whereas a similar relationship was not observed in eyes with thicker corneas. A correlation between IOP values and keratometry in the group with CCT<600 μm was not detected with any of the tonometry methods. In thicker corneas, a positive correlation was found for GAT and mean keratometry values (R=0.369, P=0.005). CONCLUSION: The same method should always be chosen for routine IOP control, and measurements obtained by different methods cannot be compared. All analysed tonometry methods are dependent on CCT; thus, CCT should be taken into consideration for both diagnostics and monitoring.     

中国人眼颅压力梯度参考区间的临床研究

目的探讨中国人群眼颅压力梯度参考区间,为建立基于眼颅压力梯度的开角型青光眼诊疗新体系提供理论标准。 方法横断面研究。对2010年8月至2019年8月首都医科大学附属北京同仁医院神经内科需行腰椎穿刺的受试者共200例。其中,男性97例,女性103例,年龄区间12~79岁,平均(47.0±14.7)岁。对受试者进行眼压、颅压及全身基本参数测量。性别资料采用频数和百分比描述;年龄、身高、体重、眼压、颅内压、平均动脉压、体质指数及眼颅压力梯度等连续定量资料采用 ±s描述。对于少量缺失数据,采用马尔科夫链蒙特卡洛模拟(MCMC)对缺失数据进行多重插补。采用95%分位数法确定参考值范围,对于连续定量资料的多组间比较采用单因素方差分析,两两比较采用两独立样本t检验。 结果根据全体受试者测定人群眼压参考区间为9.015 mmHg~20.265 mmHg(1 mmHg＝0.133 kPa)。人群颅压参考区间为6.179 mmHg~14.921 mmHg。人群眼颅压力梯度参考区间为-2.987 mmHg~11.047 mmHg。眼颅压力梯度临床诊疗参考区间为0.423 mmHg~10.508 mmHg。以年龄进行分组,<30岁人群眼颅压力梯度参考区间为-2.968 mmHg~9.028 mmHg;30岁~50岁人群眼颅压力梯度参考区间为-2.466 mmHg~11.606 mmHg;>50岁人群眼颅压力梯度参考区间为-2.466 mmHg~11.606 mmHg。三组间眼颅压力梯度差异无统计学意义(F＝2.041,P>0.05)。以性别进行分组,男性眼颅压力梯度参考区间为-2.769 mmHg~10.089 mmHg;女性眼颅压力梯度参考区间为-3.137 mmHg~11.877 mmHg。两组间眼颅压力梯度的差异无统计学意义(t＝-1.413,P>0.05)。以体质指数(BMI)进行分组,BMI<21 kg/m²的人群眼颅压力梯度参考区间为-1.437 mmHg~11.577 mmHg;21 kg/m²2的人群眼颅压力梯度参考区间为-3.046 mmHg~11.026 mmHg;BMI>23 kg/m²的人群眼颅压力梯度参考区间为-3.947 mmHg~10.087 mmHg。不同BMI分组间,眼颅压力梯度差异有统计学意义(F＝6.109,P<0.05)。 结论眼颅压力梯度临床诊疗参考区间为0.423 mmHg~10.508 mmHg,可作为开角型青光眼临床诊疗的新指标。同时,还为开角型青光眼病因学诊断及个体化治疗的进一步深入研究,提供新的实践基础与研究方向。     

Responsiveness and minimal clinically important difference of the Chinese version of the Low Vision Quality of Life Questionnaire after cataract surgery

AIM: To investigate the Chinese version of the Low Vision Quality of Life Questionnaire (CLVQOL) as an instrument for obtaining clinically important changes after cataract surgery. METHODS: Patients underwent cataract surgery in Shanghai General Hospital, Shanghai Jiao Tong University, who fit the inclusion criteria were recruited. Two CLVQOLs were administered, including a preoperative CLVQOL and a CLVQOL at the end of the 3mo follow-up period, and were completed using face-to-face interviews or phone interviews conducted by trained investigators. The minimal clinically important difference (MCID) was calculated using an anchor-based method and a distribution method. In addition, the responsiveness of the questionnaire was measured. RESULTS: A total of 155 residents were enrolled. The average visual acuity (VA) preoperatively was 0.08 (SD=0.05), and it increased to 0.47 (SD=0.28) at the end of follow-up. Statistically significant positive changes in the CLVQOL scores indicated significant improvement of vision related quality of life after cataract surgery. With the larger value between the two results as the final value, the MCID values of the CLVQOL (scores of the four scales as well as the total score) were 8.94, 2.61, 4.34, 3.10 and 17.63, respectively. The CLVQOL has both good internal and external responsiveness. CONCLUSION: CLVQOL scores are appropriate instruments for obtaining clinically important changes after cataract surgery. This study is an effective exploration for establishing cataract surgery efficacy standards, which helps clinical and scientific research workers in ophthalmology to gain a more in-depth understanding when using CLVQOL.     

CFTR基因变异致囊性纤维化1例报告并文献复习

目的探讨中国人群囊性纤维化基因型与临床表型的关系。方法回顾分析2015年3月收治的1例囊性纤维化患儿的临床资料,并复习相关文献。结果患儿,女,生后不久开始出现反复咳嗽、咳痰,肺部感染。9岁就诊时有重度营养不良,杵状指(趾),副鼻窦区压痛,双肺散在湿罗音;实验室检查提示胰腺炎;影像学检查提示合并鼻窦炎及支气管扩张;全外显子基因组测序示CFTR基因复合杂合变异,等位基因1,c.1766+5GT(NM_000492.3)剪接突变;等位基因2,c.2805delA:p.L935fs(NM_000492)移码突变;检出基因型匹配囊性纤维化临床表型。检索建库至2018年7月中国知网、万方及PubMed数据库,以"囊性纤维化"和"基因"为关键词组合检索,共检索到7篇文献,报道9例包含c.1766+5GT位点变异的囊性纤维化患儿,加上该例共10例。10例患儿均为中国人,且均以反复咳嗽、咳痰等肺部感染为主要表现,多数合并支气管扩张,仅部分合并胰腺功能不全。结论 c.1766+5GT位点可能是中国人特有的CFTR基因变异位点,与c. 2805 delA:p.L 935 fs变异构成新的复合杂合变异,其临床表型主要以呼吸道感染为主,较少累及消化道。     

中药汤剂治疗奥氮平药物副反应的临床经验

目的:分析总结中药汤剂治疗奥氮平药物副反应的临床经验。方法:调查服用奥氮平1月以上的精神病患者,统计服用药物后较常出现的中医证候及舌脉象,类推奥氮平的中医“药毒”特性;将60例受试者随机分为2组,其中奥氮平合并服用中药汤剂的为治疗组,中药汤剂根据辨证论治选用温胆汤、玉女煎、补中益气汤、补脾胃泻阴火升阳汤加减治疗,对照组服用奥氮平合并安慰剂,观察治疗前、治疗1月、2月后中医证候评分及糖脂代谢指标的前后变化及组间差异,对疗效进行评估。结果:服用奥氮平1月前后比较,受试者便秘、纳多、肥胖、口干、脉数、精神疲倦、苔厚腻、肢体乏力、舌红、舌淡、脉滑、舌边齿痕、舌胖大、苔白的中医证候评分较前显著升高,具有统计学差异(P<0.05或P<0.01)。中医辨证分型为痰湿内阻证、胃热伤津证、脾气亏虚证和兼有脾虚、痰湿、胃热证。运用传统中医分析中药药性及功效的方法,类推奥氮平的“药毒”性热,入脾胃经,具有胃热伤津、伤脾生湿的作用。经过2月中药汤剂治疗后,试验组中医证候总分较前显著降低,差异具有统计学意义(P<0.01);试验组与对照组比较治疗后中医证候总分差异有显著性(P<0.01)。治疗后试验组与对照组的空腹血糖、餐后2h血糖、血清胰岛素、总胆固醇、甘油三酯、高密度脂蛋白、低密度脂蛋白、体重、腰围、腰臀比及BMI值差异有显著性(P<0.05)。结论:临床上依据奥氮平“药毒”特性来辨证论治,运用中药汤剂治疗可以显著减少奥氮平所致的药物副反应。     

行气散外敷治疗结核性肠梗阻的疗效观察

目的:探讨中西医结合治疗结核性腹膜炎伴粘连性肠梗阻的疗效。方法:96例结核性腹膜炎合并肠梗阻患者随机分为治疗组及对照组,每组各48例,治疗组及对照组均在抗痨治疗的基础上给予常规禁食、持续胃肠减压、抗感染、补液支持等治疗,治疗组则在此基础上加用中药行气散外敷治疗。结果:治疗组疗效有效率为91.67%,优于对照组的64.60%(P<0.05);且治疗组的住院时间与对照组相比明显缩短,优于对照组(P<0.05)。结论:西医常规治疗的基础上结合中药行气散外敷治疗,具有良好的临床效果,在抗痨治疗的基础上能有效缓解肠梗阻,同时缩短住院时间,值得在临床上推广应用。     

基于Innography平台的成都中医药大学专利分析

本研究借助于专业的专利分析Innography平台结合广东省专利大数据应用服务系统,对成都中医药大学专利的申请历史、现状、专利发展趋势、专利申请国别分布、所聚焦的研究领域、研究技术点,高强度专利等方面进行了综合分析,旨在为成都中医药大学的专利保护、布局及科研能力提升提供参考。     

腹康理气汤促进腹部手术后肠道功能恢复临床观察

目的：运用腹康理气汤进行术后肠道功能恢复。方法腹部手术后6~24h给予腹康理气汤口服或保留灌肠。结果治疗组374例患者中，显效272例，有效84例，无效18例，总有效率95.19%；对照组178例患者中，显效70例，有效80例，无效28例，总有效率84.27%。根据统计学处理有统计学意义。结论腹康理气汤具有促进腹部手术后肠道功能恢复的作用。